{"title":"接受生物制剂治疗的银屑病患者真菌感染的风险:一项回顾性单中心队列研究。","authors":"Yoshihito Minami MD , Junichiro Hiruma MD, PhD , Kazuharu Harada PhD , Kazuki Fujimori MD , Risa Suzuki MD , Miho Mori MD , Masahiro Okura MD , Namiko Abe MD, PhD , Kazutoshi Harada MD, PhD , Yukari Okubo MD, PhD","doi":"10.1016/j.jaad.2024.09.037","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The risk of fungal infection in patients with psoriasis receiving biologics is not fully understood in clinical practice.</div></div><div><h3>Objective</h3><div>To assess the incidence and the risk of fungal infection onset in patients with psoriasis receiving biologics.</div></div><div><h3>Methods</h3><div>A retrospective cohort study of 592 psoriasis cases treated with biologics at a single center.</div></div><div><h3>Results</h3><div>Seventy-three (12.3%) of the 592 cases involved a fungal infection. Fungal infection occurrence was more frequently associated with the use of interleukin (IL) 17 inhibitors than of other biologics. The risk factors of fungal infection were the type of biologic agent (<em>P</em> = .004), age at the start of biologic therapy (odds ratio, 1.04; 95% CI, 1.02-1.06), and diabetes mellitus (odds ratio, 2.40; 95% CI, 1.20-4.79).</div></div><div><h3>Limitations</h3><div>The present, retrospective study did not include patients who did not receive biologic therapy. Moreover, the type of biologic agent used was changed in many cases.</div></div><div><h3>Conclusions</h3><div>Patients with psoriasis treated with IL-17 inhibitors were more likely to cause fungal infections, especially candidiasis, than other biologics. Moreover, the age at the start of biologic therapy and diabetes mellitus onset were also independent risk factors of fungal infection.</div></div>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"92 1","pages":"Pages 108-115"},"PeriodicalIF":12.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of fungal infection in patients with psoriasis receiving biologics: A retrospective single-center cohort study\",\"authors\":\"Yoshihito Minami MD , Junichiro Hiruma MD, PhD , Kazuharu Harada PhD , Kazuki Fujimori MD , Risa Suzuki MD , Miho Mori MD , Masahiro Okura MD , Namiko Abe MD, PhD , Kazutoshi Harada MD, PhD , Yukari Okubo MD, PhD\",\"doi\":\"10.1016/j.jaad.2024.09.037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The risk of fungal infection in patients with psoriasis receiving biologics is not fully understood in clinical practice.</div></div><div><h3>Objective</h3><div>To assess the incidence and the risk of fungal infection onset in patients with psoriasis receiving biologics.</div></div><div><h3>Methods</h3><div>A retrospective cohort study of 592 psoriasis cases treated with biologics at a single center.</div></div><div><h3>Results</h3><div>Seventy-three (12.3%) of the 592 cases involved a fungal infection. Fungal infection occurrence was more frequently associated with the use of interleukin (IL) 17 inhibitors than of other biologics. The risk factors of fungal infection were the type of biologic agent (<em>P</em> = .004), age at the start of biologic therapy (odds ratio, 1.04; 95% CI, 1.02-1.06), and diabetes mellitus (odds ratio, 2.40; 95% CI, 1.20-4.79).</div></div><div><h3>Limitations</h3><div>The present, retrospective study did not include patients who did not receive biologic therapy. Moreover, the type of biologic agent used was changed in many cases.</div></div><div><h3>Conclusions</h3><div>Patients with psoriasis treated with IL-17 inhibitors were more likely to cause fungal infections, especially candidiasis, than other biologics. Moreover, the age at the start of biologic therapy and diabetes mellitus onset were also independent risk factors of fungal infection.</div></div>\",\"PeriodicalId\":17198,\"journal\":{\"name\":\"Journal of the American Academy of Dermatology\",\"volume\":\"92 1\",\"pages\":\"Pages 108-115\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Academy of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0190962224028950\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0190962224028950","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Risk of fungal infection in patients with psoriasis receiving biologics: A retrospective single-center cohort study
Background
The risk of fungal infection in patients with psoriasis receiving biologics is not fully understood in clinical practice.
Objective
To assess the incidence and the risk of fungal infection onset in patients with psoriasis receiving biologics.
Methods
A retrospective cohort study of 592 psoriasis cases treated with biologics at a single center.
Results
Seventy-three (12.3%) of the 592 cases involved a fungal infection. Fungal infection occurrence was more frequently associated with the use of interleukin (IL) 17 inhibitors than of other biologics. The risk factors of fungal infection were the type of biologic agent (P = .004), age at the start of biologic therapy (odds ratio, 1.04; 95% CI, 1.02-1.06), and diabetes mellitus (odds ratio, 2.40; 95% CI, 1.20-4.79).
Limitations
The present, retrospective study did not include patients who did not receive biologic therapy. Moreover, the type of biologic agent used was changed in many cases.
Conclusions
Patients with psoriasis treated with IL-17 inhibitors were more likely to cause fungal infections, especially candidiasis, than other biologics. Moreover, the age at the start of biologic therapy and diabetes mellitus onset were also independent risk factors of fungal infection.
期刊介绍:
The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.